Table 2. Association between polymorphisms in DNA repair and cell-cycle genes and risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy.
Patients without telangiectasia
|
Patients with telangiectasia
|
||||||
---|---|---|---|---|---|---|---|
Gene polymorphism | Genotype | N=278 | % | N=131 | % | ORa | 95% CI |
APEX1 | TT | 71 | 25.9 | 39 | 30.7 | 1.00 | |
Asp148Gln | TG | 134 | 48.9 | 65 | 51.2 | 1.03 | 0.58–1.83 |
rs3136820 | GG | 69 | 25.2 | 23 | 18.1 | 0.66 | 0.33–1.32 |
TG+GG | 203 | 74.1 | 88 | 69.3 | 0.90 | 0.53–1.54 | |
XRCC1 | TT | 94 | 34.2 | 43 | 33.9 | 1.00 | |
−77 T>C | TC | 136 | 49.5 | 54 | 42.5 | 0.97 | 0.56–1.67 |
rs3213245 | CC | 45 | 16.4 | 30 | 23.6 | 1.87 | 0.94–3.70 |
TC+CC | 181 | 65.8 | 84 | 66.1 | 1.17 | 0.71–1.95 | |
XRCC1 | CC | 242 | 88.3 | 117 | 92.1 | 1.00 | |
Arg194Trp | CT | 30 | 11 | 10 | 7.9 | 0.58 | 0.24–1.40 |
rs1799782 | TT | 2 | 0.7 | 0 | 0 | 0 | 0 |
CT+TT | 32 | 11.7 | 10 | 8 | 0.57 | 0.24–1.38 | |
XRCC1 | GG | 244 | 88.4 | 118 | 92.9 | 1.00 | |
Arg280His | GA | 30 | 10.9 | 9 | 7.1 | 0.49 | 0.19–1.24 |
rs25489 | AA | 2 | 0.7 | 0 | 0 | 0 | 0 |
GA+AA | 32 | 11.6 | 9 | 7.1 | 0.43 | 0.17–1.09 | |
XRCC1 | GG | 112 | 40.6 | 50 | 39.4 | 1.00 | |
Arg399Gln | GA | 120 | 43.5 | 63 | 49.6 | 1.09 | 0.65–1.82 |
rs25487 | AA | 44 | 15.9 | 14 | 11 | 0.63 | 0.29–1.37 |
GA+AA | 164 | 59.4 | 77 | 60.6 | 0.96 | 0.59–1.57 | |
XRCC2 | GG | 236 | 85.5 | 113 | 89 | 1.00 | |
Arg188His | GA | 38 | 13.8 | 13 | 10.2 | 0.83 | 0.39–1.76 |
rs3218536 | AA | 2 | 0.7 | 1 | 0.8 | 1.05 | 0.08–13.93 |
GA+AA | 40 | 14.5 | 14 | 11 | 0.84 | 0.41–1.74 | |
XRCC3 | CC | 104 | 38 | 45 | 35.4 | 1.00 | |
Thr241Met | CT | 126 | 46 | 63 | 49.6 | 1.05 | 0.62–1.79 |
rs861539 | TT | 44 | 16.1 | 19 | 15 | 1.12 | 0.53–2.40 |
CT+TT | 170 | 62 | 82 | 64.6 | 1.07 | 0.65–1.77 | |
NBS1 | GG | 120 | 43.5 | 53 | 41.7 | 1.00 | |
Glu185Gln | GC | 137 | 49.6 | 58 | 45.7 | 0.92 | 0.55–1.54 |
rs1805794 | CC | 19 | 6.9 | 16 | 12.6 | 2.14 | 0.88–5.19 |
GC+CC | 156 | 56.5 | 74 | 58.3 | 1.06 | 0.65–1.72 | |
XPD | GG | 120 | 43.8 | 42 | 33.3 | 1.00 | |
Asp312Asn | GA | 117 | 42.7 | 69 | 54.8 | 1.51 | 0.89–2.55 |
rs1799793 | AA | 37 | 13.5 | 15 | 11.9 | 0.91 | 0.41–2.01 |
GA+AA | 154 | 56.2 | 84 | 66.6 | 1.36 | 0.82–2.24 | |
XPD | AA | 109 | 39.6 | 42 | 33.3 | 1.00 | |
Lys751/Gln | AC | 133 | 48.4 | 65 | 51.6 | 1.15 | 0.68–1.95 |
rs13181 | CC | 33 | 12 | 19 | 15.1 | 1.21 | 0.57–2.58 |
AC+CC | 166 | 60.4 | 84 | 66.6 | 1.16 | 0.70–1.92 | |
P21 | CC | 242 | 87.7 | 110 | 86.6 | 1.00 | |
Ser31Arg | CA | 31 | 11.2 | 17 | 13.4 | 1.54 | 0.71–3.32 |
rs1801270 | AA | 3 | 1.1 | 0 | 0 | 0 | 0 |
CA+AA | 34 | 12.3 | 17 | 13.4 | 1.27 | 0.60–2.68 | |
TP53 | GG | 160 | 58.0 | 64 | 50.4 | 1.00 | |
Arg72Pro | GC | 96 | 34.8 | 49 | 38.6 | 1.67 | 0.98–2.83 |
rs1042522 | CC | 20 | 7.3 | 14 | 11 | 1.62 | 0.71–3.70 |
GC+CC | 116 | 40 | 63 | 49.6 | 1.66 | 1.02–2.71 | |
TP53 | A1A1 | 214 | 77.6 | 87 | 68.5 | 1.00 | |
PIN3 | A1A2 | 56 | 20.3 | 40 | 31.5 | 2.14 | 1.23–3.71 |
A2A2 | 6 | 2.2 | 0 | 0 | 0 | 0 | |
A1A2+A2A2 | 62 | 22.4 | 40 | 31.5 | 1.95 | 1.13–3.37 | |
CI=confidence interval; NTD=normalised total dose; OR=odds ratio.
Adjusted for NTD, age at the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, <20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).